What is it about?
In this study, we looked for HBV mutations that were primarily associated to resistance to the new direct-acting antiviral drugs used to treat chronic HBV infection. Those mutations can appear spontaneously either in treatment-naive patients or treated patients.
Featured Image
Why is it important?
Identification of HBV resistance strains in treatment-naïve patients is necessary to prevent inadequate management and treatment of those resistant patients, and ultimately prevent increase the risk of developing multidrug-resistant HBV.
Perspectives
Our perspectives are to create and to maintain a HBV/HCV drug-resistance tracking system to help the physicians to better manage the treatment of their patients and discover new drug–related mutations.
Luciano Silva
Fundação Oswaldo Cruz
Read the Original
This page is a summary of: Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B, Infection and Drug Resistance, July 2017, Dove Medical Press,
DOI: 10.2147/idr.s135420.
You can read the full text:
Contributors
The following have contributed to this page
